Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system

Clinical Therapeutics

Volumn 32, Issue 9, 2010, Pages 1578-1596

  Emerson, Christopher R ^a,b   Marzella, Nino ^a,c  

^a LONG ISLAND UNIVERSITY   (United States)

^b LENOX HILL HOSPITAL   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Dexlansoprazole; Esophagitis; Gastroesophageal reflux; Proton pump inhibitors; TAK 390MR

Indexed keywords

AMINOPHYLLINE; DEXLANSOPRAZOLE; DIAZEPAM; ESOMEPRAZOLE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; MOXIFLOXACIN; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; TAK 390MR; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL PAIN; ARTICLE; BLOATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DELAYED DRUG RELEASE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; FLATULENCE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL PAIN; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; HEADACHE; HEARTBURN; HERNIA; HUMAN; MORNING DOSAGE; NAUSEA AND VOMITING; NON EROSIVE REFLUX DISEASE; NONCARDIAC CHEST PAIN; NONHUMAN; NOSE CONGESTION; PARALYSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REFLUX ESOPHAGITIS; RESPIRATORY TRACT DISEASE; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANIMALS; DELAYED-ACTION PREPARATIONS; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 77958192847     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.08.008     Document Type: Article

References (52)

1. DeVault KR, Castell DO Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005, 100:190-200. American College of Gastroenterology.
2. Donnellan C, Sharma N, Preston C, Moayyedi P Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2004, (4):CD003245.
3. Dent J, El-Serag HB, Wallander M, Johansson S Epidemiology of gastro-oesophageal reflux disease: A systematic review. Cut 2005, 54:710-717.
4. Fass R, Shapiro M, Dekel R, Sewell J Systematic review: Proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next?. Aliment Pharmacol Ther 2005, 22:79-94.
5. Spechler SJ Clinical practice. Barrett's esophagus. N Engl J Med 2002, 346:836-842.
6. Wang KK, Sampliner RE Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008, 103:788-797. Practice Parameters Committee of the American College of Gastroenterology.
7. Cossentino MJ, Wong RK Barrett's esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis 2003, 14:128-135.
8. Lagergren J, Bergström R, Lindgren A, Nyrén O Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999, 340:825-831.
9. Spechler SJ Barrett's esophagus Gl Motil Online. Accessed November 21, 2009. http://www.nature.com/gimo/contents/pt1/full/gimo44.html.
10. Dean BB, Gano AD, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004, 2:656-664.
11. Katz PO, Scheiman JM, Barkun AN Review article: Acidrelated disease-what are the unmet clinical needs?. Aliment Pharmacol Ther. 2006, 23(Suppl 2):9-22.
12. Hunt RH Review article: The unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Ailment Pharmacol Ther 2005, 22(Suppl 3):10-19. [published correction appears in Aliment Pharmacol Ther.2006;23:A377].
13. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002, 97:575-583.
14. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol 2001, 96:656-665. Esomeprazole Study Investigators.
15. Fennerty M, Johanson J, Hwang C, Sostek M Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005, 21:455-463.
16. Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: The EXPO study. Aliment Pharmacol Ther 2005, 21:739-746. EXPO Study Investigators.
17. Aciphex (rabeprazole) [package insert] 2009, Eisai Inc, Woodcliff Lake, NJ.
18. Nexium (esomeprazole) [package insert] 2009, AstraZeneca Pharmaceuticals LP, Wilmington, Del.
19. Prilosec (omeprazole) [package insert] 2008, AstraZeneca Pharmaceuticals LP, Wilmington, Del.
20. Protonix (pantoprazole) [package insert] 2008, Wyeth Pharmaceuticals Inc, Philadelphia, Pa.
21. Prevacid (lansoprazole) [package insert] 2009, Takeda Pharmaceuticals America, Inc, Deerfield, Ill.
22. Kapidex (dexlansoprazole) [package insert] 2009, Takeda Pharmaceuticals America, Inc, Deerfield, Ill.
23. Arimori K, Yasuda K, Katsuki H, Nakano M Pharmacokinetic differences between lansoprazole enantiomers in rats. J Pharm Pharmacol 1998, 50:1241-1245.
24. Masa K, Hamada A, Arimori K, et al. Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs. Biol Pharm Bull. 2001, 24:274-277.
25. Vakily M, Zhang W, Wu J, et al. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: A combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009, 25:627-638.
26. Wu J, Vakily M, Witt G, Mulford D TAK-390MR vs lansoprazole (LAN) for maintenance of drug concentration above a threshold which corresponds to higher %-time pH >4. Am J Gastroenterol. 2007, 102(Suppl 2S):S124. Abstract 15.
27. Lee RD, Vakily M, Mulford D, et al. Clinical trial: The effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor-evidence for dosing flexibility. Aliment Pharmacol Ther. 2009, 29:824-833.
28. Czerniak R, Vakily M, Wu J TAK-390MR, a novel dual delayed release formulation of a PPI, is bioequivalent when administered as granules sprinkled over applesauce or as an intact capsule. Am J Gastroenterol. 2008, 103(Suppl 1S):S4-S5. Abstract 12.
29. Grabowski B, Lee R, Czerniak R Metabolism and excretion of (14C) TAK-390 in healthy male subjects. DrugMetab Rev 2008, 40(Suppl 3):194-195.
30. Lee RD, Wu J, Vakily M, Mulford D Effect of hepatic impairment on the pharmacokinetics of TAK-390MR (modified release). Clin Pharmacol Ther. 2008, 83(Suppl 1):S95. Abstract PIII-75.
31. Vakily M, Zhang W, Wu J, Mulford D Effect of age and gender on the pharmacokinetics of a single oral dose of TAK-390MR (modified release). Clin Pharmacol Ther. 2008, 83(Suppl 1):S96. Abstract PIII-78.
32. Vakily M, Lee RD, Wu J, et al. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: Results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig 2009, 29:35-50.
33. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of Clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials. Lancet 2009, 374:989-997.
34. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and Clopidogrel. CMAJ 2009, 180:713-718.
35. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of Clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009, 301:937-944.
36. Guard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of Clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) Study. J Am Coll Cardiol 2008, 51:256-260.
37. Plavix (Clopidogrel) [package insert] 2009, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Bridgewater, NJ.
38. Zhang W, Wu J, Atkinson SN Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. J Clin Pharmacol. 2009, 49:444-454.
39. Zhang W, Wu J, Atkinson S Effects of TAK-390MR on plasma gastrin levels in healthy adults. Clin Pharmacol Ther. 2007, 81(Suppl 1):S26. Abstract PI-44.
40. Vakily M, Wu J, Atkinson SN Lack of electrocardiographic effect of dexlansoprazole MR, a novel modifiedrelease formulation of the proton pump inhibitor dexlansoprazole, in healthy participants. J Clin Pharmacol 2009, 49:1447-1455.
41. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: Healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies. Aliment Pharmacol Ther 2009, 29:731-741.
42. Metz DC, Howden CW, Perez MC, et al. Clinical trial: Dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther 2009, 29:742-754.
43. Mody R, Larsen L, Perez M, et al. TAK-390MR maintains relief of gastroesophageal reflux disease (GERD) symptoms and improvements in quality of life in GERD patients with healed erosive esophagitis. Am J Gastroenterol. 2008, 103(Suppl 1):S23. Abstract 57.
44. Howden CW, Larsen LM, Perez MC, et al. Clinical trial: Efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis-maintenance of healing and symptom relief. Aliment Pharmacol Ther 2009, 30:895-907.
45. Fass R, Chey WD, Zakko SF, et al. Clinical trial: The effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with nonerosive reflux disease. Aliment Pharmacol Ther 2009, 29:1261-1272.
46. Fass R, Johnson D, Orr W, et al. Dexlansoprazole MR for treatment for nocturnal heartburn in patients with symptomatic nonerosive GERD. Am J Gastroenterol. 2009, 104(Suppl 3):S11-S12. Abstract 29.
47. Orr W, Fass R, Johnson D, et al. Effects of dexlansoprazole MR on sleep quality and health-related quality of life (HRQOL) in patients with symptomatic nonerosive GERD. Am J Gastroenterol. 2009, 104(Suppl 3):S12. Abstract 30.
48. Johnson D, Fass R, Orr W, et al. Effect of dexlansoprazole MR on improving work productivity and daily activities in patients with symptomatic nonerosive GERD. Am J Gastroenterol. 2009, 104(Suppl 3):S12-S13. Abstract 31.
49. Bronner M, Perez MC, Dabholkar A, Palo W Gastric biopsy results from patients treated with dexlansoprazole MR, a proton pump inhibitor with a dual delayed release formulation. Am J Gastroenterol. 2009, 104(Suppl 3):S5. Abstract 13.
50. Drugstore.com. Drug prices and information Accessed November 23, 2009. http://www.drugstore.com/pharmacy/drugindex/default.asp?
51. Metz DC, Vakily M, Dixit T, Mulford D Review article: Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009, 29:928-937.
52. Miner P, Katz PO, Chen Y, Sostek M Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study. Am J Gastroenterol 2003, 98:2616-2620.